Clinical Trial Detail

NCT ID NCT02716038
Title Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Columbia University
Indications

lung non-small cell carcinoma

Therapies

Atezolizumab + Carboplatin + Nab-paclitaxel

Age Groups: adult

No variant requirements are available.